Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene

Cancer Gene Therapy

Volumn 4, Issue 4, 1997, Pages 229-238

  Green, Nicola K ^a   Youngs, Denise J ^a   Neoptolemos, John P ^a   Friedlos, Frank ^b   Knox, Richard J ^b   Springer, Caroline J ^b   Anlezark, Gillian M ^c   Michael, N Paul ^c   Melton, Roger G ^c   Ford, Martin J ^d   Young, Lawrence S ^a   Kerr, David J ^a   Searle, Peter F ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

^d GLAXOSMITHKLINE   (United Kingdom)

Author keywords

5 (aziridin 1 yl) 2,4 dinitrobenzamide; CB1954; Colorectal cancer; Enzyme prodrug therapy; Escherichia coli nitroreductase; Gene therapy; Pancreatic cancer; Retroviral vectors

Indexed keywords

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; 5-(1-AZIRIDINYL)-2,4-DINITROBENZAMIDE; ANTINEOPLASTIC AGENT; AZIRIDINE DERIVATIVE; NITROREDUCTASE; PRODRUG;

ARTICLE; CELL CULTURE; COLORECTAL TUMOR; DOSE RESPONSE; ESCHERICHIA COLI; GENE THERAPY; GENE VECTOR; GENETICS; HUMAN; PANCREAS TUMOR; RETROVIRUS;

ANTINEOPLASTIC AGENTS; AZIRIDINES; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; ESCHERICHIA COLI; GENE THERAPY; GENETIC VECTORS; HUMANS; NITROREDUCTASES; PANCREATIC NEOPLASMS; PRODRUGS; RETROVIRIDAE; TUMOR CELLS, CULTURED;

EID: 0031183755     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Parkin DM, Muir CS, Whelan SL, et al. Cancer incidence in five continents. IARC Sci Publ No 120. 1992;6:1-1033.
2. Bramhall SR, Neoptolemos JP. Adjuvant therapy. Current Pract Surg. 1994;6:161-166.
3. Bramhall SR, Allum WH, Jones AG, et al. Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands; an epidemiological study. Br J Surg. 1995;82:111-115.
4. Fisher DE. Apoptosis in cancer therapy: crossing the threshold. Cell. 1994;78:539-542.
5. De Takats PG, Kerr DJ, Poole CJ, et al. Hepatic arterial chemotherapy for metastatic colorectal carcinoma. Br J Cancer. 1994;69:372-378.
6. Cobb LM, Connors TA, Elson LA, et al. 2,4-Dinitro-5-ethyleneiminobenzamide (CB1954): a potent and selective inhibitor of growth of the Walker carcinoma 256. Biochem Pharmacol. 1969;18:1519-1527.
7. Knox RJ, Boland M, Friedlos F, et al. The nitroreductase enzyme in Walker cells that activates 5-(aziridin-l-yl)-2,4-dinitrobenzamide (CB 1954) to 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone)(EC 1;6:99.2). Biochem. Pharmacol. 1988;37:4671-4677.
8. Boland MP, Knox RJ, Roberts JJ. The differences in kinetics of rat and human DT diaphorase result in a differential sensitivity of derived cell lines to CB1954 (5-(aziridin-1-yl)-2,4-dinitrobenzamide). Biochem Pharmacol. 1991;41:867-875.
9. Huber BE, Richards CA, Krenitsky TA. Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy. Proc Natl Acad Sci USA. 1991;88:8039-8043.
10. Culver KW, Ram Z, Wallbridge S, et al. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science. 1992;256:1550-1552.
11. Caruso M, Panis Y, Gagandeep S. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc Natl Acad Sci USA. 1993;90: 7024-7028.
12. DiMaio JM, Clary BM, Via DF, et al. Directed enzyme pro-drug gene therapy for pancreatic cancer. Surgery. 1994;116:205-213.
13. Mullen CA, Kilstrup M, Blaese RM. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc Natl Acad Sci USA. 1992;89:33-37.
14. Austin EA, Huber BE. A first step in the development of gene therapy for colorectal carcinoma: cloning, sequencing, and expression of Escherichia coli cytosine deaminase. Mol Pharmacol. 1993;43:380-387.
15. Harris JD, Gutierrez AA, Hurst HC, et al. Gene therapy for cancer using tumour-specific prodrug activation. Gene Therapy. 1994;1:170-175.
16. Huber BE, Austin EA, Richards CA, et al. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase genesignificant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci USA. 1994;91:8302-8306.
17. Freeman SM, Abboud CN, Whartenby KA, et al. The bystander effect: tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 1993;53: 5274-5283.
18. Anlezark GM, Melton RG, Sherwood RF, et al. The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) - I: Purification and properties of a nitroreductase enzyme from Escherichia coli - a potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT). Biocliem Pharmacol. 1992;44:2289-2295.
19. Michael NP, Brehm JK, Anlezark GM, et al. Physical characterization of the Escherichia coli B gene encoding nitroreductase and its overexpression in Escherichia coli K12. FEMS Microbiol Lett. 1994;124:195-202.
20. Miller AD, Rosman GJ. Improved retroviral vectors for gene transfer and expression. BioTechniques. 1989;7:980-988.
21. Chambers SP, Prior SE, Barstow DA, et al. The pMTL cloning vectors: I. Improved polylinker regions to facilitate the generation of sonicated DNA for nucleotide sequencing. Gene. 1988;68:139-149.
22. Brehm JK, Chambers SP, Brown KJ, et al. Molecular cloning and sequence determination of the Bacillus stearothermophilus NCA1503 superoxide dismutase gene and its overexpression in Escherichia coli. Appl Microbiol Biotechnol. 1991;36:358-363.
23. Kozak M. Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes. Cell. 1986;44:283-292.
24. Markowitz D, Goff S, Bank A. Construction and use of a safe and efficient amphotropic packaging cell line. Virology. 1988;167:400-406.
25. Morgenstern JP, Land H. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res. 1990;18:3587-3596.
26. Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxic assay for anticancer-drug screening. J Natl Cancer Inst. 1990;82:1107-1112.
27. Whitehead TP, Thorpe GHG, Carter TJN, et al. Enhanced chemiluminescence procedure for sensitive detection of peroxidase-labelled conjugates in immunoassay. Nature. 1983;305:153-159.
28. Knox RJ, Friedlos F, Biggs PJ, et al. Identification, synthesis and properties of 5-(aziridin-1-yl)-2-nitro-4-nitrosobenzamide, a novel DNA crosslinking agent derived from CB1954. Biochem Pharmacol. 1993;46:797-803.
29. Culver KW, Vangilder J, Link CJ, et al. Gene therapy for the treatment of malignant brain tumors with in vivo tumor transduction with the herpes simplex thymidine kinase gene ganciclovir system. Human Gene Ther. 1994;5:343-379.
30. Searle PF, Green NK, Young LS, et al. Gene transfer therapy and pancreatic cancer. In: Neoptolemos JP, Lemoine N, eds. Pancreatic Cancer: Molecular and Clinical Advances. Oxford: Blackwell Science; 1996:194-213.
31. Kasahara N, Dozy AM, Kan YW. Tissue-specific targeting of retroviral vectors through ligand-receptor interactions. Science. 1994;266:1373-1376.
32. Somia NV, Zoppé M, Verma IM. Generation of targeted retroviral vectors by using single-chain variable fragment: an approach to in vivo gene delivery. Proc Natl Acad Sci USA. 1995;92:7570-7574.
33. Cosset FL, Morling FJ, Takeuchi Y, et al. Retroviral retargeting by envelopes expressing an N-terminal binding domain. J Virol. 1995;69:6314-6322.
34. Nilsson O, Johansson C, Glimelius B, et al. Sensitivity and specificity of CA242 in gastrointestinal cancer - a comparison with CEA, CA50 and CA 19-9. Br J Cancer. 1992;65: 215-221.
35. Richards CA, Austin EA, Huber BE'. Transcriptional regulatory sequences of carcinoembryonic antigen: identification and use with cytosine deaminase for tumor-specific gene therapy. Hum Gene Ther. 1995;6:881-893.
36. Phillips BJ, Ambrose EJ. Cell hybridization study of resistance to alkylating agents. Nature. 1971;231:146-147.
37. Roberts JJ, Friedlos F, Knox RJ. CB1954 (2,4-dinitro-5-aziridinyl benzamide) becomes an interstrand crosslinking agent in Walker tumour cells. Biochem Biophys Res Commun. 1986;140:1073-1078.
38. Knox RJ, Friedlos F, Boland M. The bioactivation of CB1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT). Cancer Metastasis Rev. 1993;12:195-212.
39. Knox RJ, Friedlos F, Jarman M, et al. A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in Walker carcinoma cells. Biochem Pharmacol. 1988;37:4661-4669.
40. Kavi BR, Bhisey AN, Bapat CV. Effect of standard chemotherapeutic agents on human tumour cells in vitro. Indian J Cancer. 1975;12:295-301.
41. Workman P, Morgan JE, Talbot K, et al. CB1954 revisited II. Toxicity and anti-tumour activity. Cancer Chemother Pharmacol. 1986;16:9-14.
42. Friedlos F, Knox RJ. Metabolism of NAD(P)H by blood components - relevance to bioreductively activated prodrugs in a targeted enzyme therapy system. Biochem Pharmacol. 1992;44:631-635.
43. Friedlos F, Jarman M, Davies LC, et al. Identification of novel reduced pyridinium derivatives as synthetic cofactors for the enzyme DT diaphorase (NAD(P)H dehydrogenase (quinone), EC 1.6.99.2). Biochem Pharmacol. 1992;44:25-31.
44. Bridgewater JA, Springer CJ, Knox RJ, et al. Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954. EurJ Cancer. 1995;31A:2362-2370.